Last edition
News about "Ying Gong"
GV20 Therapeutics Hits Milestone in ADC Collaboration with Mitsubishi Tanabe Pharma
GV20 Therapeutics has secured a milestone payment from Mitsubishi Tanabe Pharma under their 2025 collaboration to develop the first-in-class Antibody Drug Conjugates (ADCs) using GV20’s STEAD AI–discovered tumour-targeting antibodies.
Ying Gong | 28/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members